Exelixis Presents Positive COMETRIQ Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc.

today announced the presentation of additional data from clinical trials of COMETRIQ™ (cabozantinib) in patients with progressive, metastatic medullary thyroid cancer (MTC). The data were presented this weekend at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Long-term follow-up of a phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic MTC patients treated with COMETRIQ experienced disease control (DC) and have remained progression-free for more than 2 years. A separate presentation (Abstract #6000) reports data from the prospective analysis of RET mutational status and retrospective ad hoc analysis of RAS mutational status of patients in EXAM, Exelixis' phase 3 pivotal trial of COMETRIQ in progressive, metastatic MTC. These data show